primary antibody against pdcd1 Search Results


pd-1 (pa5-j43)  (Becton Dickinson)
90
Becton Dickinson pd-1 (pa5-j43)
Pd 1 (Pa5 J43), supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/primary+antibody+against+pdcd1/pd+1++pa5+j43++antibody/us11723906-1047-40-44
Average 90 stars, based on 1 article reviews
pd-1 (pa5-j43) - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier
pd-1 antibodies  (BioMimetic Therapeutics)
90
BioMimetic Therapeutics pd-1 antibodies
Pd 1 Antibodies, supplied by BioMimetic Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/primary+antibody+against+pdcd1/sonodynamic+therapy+nanovaccine+integration+platform/pmc11347334-306-23-7
Average 90 stars, based on 1 article reviews
pd-1 antibodies - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier
anti–pd-1 mab be0146  (BioXcel Inc)
90
BioXcel Inc anti–pd-1 mab be0146
Anti–Pd 1 Mab Be0146, supplied by BioXcel Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/primary+antibody+against+pdcd1/anti+pd1+bioxcel+be0146/pmc11957693-296-11-14
Average 90 stars, based on 1 article reviews
anti–pd-1 mab be0146 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier
anti pd 1  (Novus Biologicals)
91
Novus Biologicals anti pd 1
Anti Pd 1, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/primary+antibody+against+pdcd1/PD-1+Antibody+(PDCD1%2F1410R)/pm37162249-299-0-6
Average 91 stars, based on 1 article reviews
anti pd 1 - by Bioz Stars, 2026-11
91/100 stars
  Buy from Supplier
kháng thể đơn dòng kháng pd 1  (Merck & Co)
86
Merck & Co kháng thể đơn dòng kháng pd 1
Kháng Thể đơn Dòng Kháng Pd 1, supplied by Merck & Co, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/primary+antibody+against+pdcd1/2+cov+c%C3%B3+c%E1%BB%A7a+d%E1%BA%ABn+kh%C3%A1ng+kh%E1%BA%A3+l%C3%A0+molnupiravir+n4hydroxycytidin+n%C4%83ng+ribonucleosid+sars+xu%E1%BA%A5t/10__34238_slash_tnu___jst__10280-48-1-15
Average 86 stars, based on 1 article reviews
kháng thể đơn dòng kháng pd 1 - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier
cd279 (pd-1) (eh12.1, buv737  (Becton Dickinson)
90
Becton Dickinson cd279 (pd-1) (eh12.1, buv737
Cd279 (Pd 1) (Eh12.1, Buv737, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/primary+antibody+against+pdcd1/anti+cd279/bio_rxiv__2023__11__24__565960-229-75-78
Average 90 stars, based on 1 article reviews
cd279 (pd-1) (eh12.1, buv737 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier
eh12.1 pe  (Becton Dickinson)
90
Becton Dickinson eh12.1 pe
Eh12.1 Pe, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/primary+antibody+against+pdcd1/pd+1+pe+antibody/pmc09293980__41467_2022_31880_MOESM3_ESM-18-34-37
Average 90 stars, based on 1 article reviews
eh12.1 pe - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier
pd-1 (bv421, eh12.1  (Becton Dickinson)
90
Becton Dickinson pd-1 (bv421, eh12.1
Representative flow cytometry plots gated on CD8 + T-cells for a Chro individual showing A. Cellular proliferation (CFSElow), B. IFNγ production, and C . HLA-DR⁺CD38⁺ expression. Pair-wise comparison on the percentage of CFSE low , IFNγ and HLA-DR⁺CD38⁺ expression in response to the corresponding HIV peptides (HIV-1-Gag peptide pool for Et and Chro groups and HIVConsv peptide pool for Etvac) in the presence of αPD-1, αTIM-3, αPD-1+αTIM-3 (Combo) antibodies and isotype control antibodies in D. Etvac, E. Et and F. Chro study groups. The dots represent a sample tested. The Wilcoxon matched-pairs signed ranked test was used to calculate statistical differences. P-values: ns > 0.05, *<0.05, **<0.005 and ***<0.0005.
Pd 1 (Bv421, Eh12.1, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/primary+antibody+against+pdcd1/annexin+v/bio_rxiv__2024__07__05__601669-155-25-29
Average 90 stars, based on 1 article reviews
pd-1 (bv421, eh12.1 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier
buv395-pd-1 j43  (Becton Dickinson)
90
Becton Dickinson buv395-pd-1 j43
Clinical expression <t>of</t> <t>PD-1</t> and IL-2 receptors on lymphocytes in head and neck cancer (A and B) Cell mapping of HNSCC datasets from TISCH single-cell RNA sequencing database. (C) Single-cell RNA sequencing of TISCH HNSCC datasets showing PD-1 expression being localized primarily on T cells. (D) Heatmap showing differential expression of PD-1 across immune cell types gathered from TISCH single-cell RNA sequencing databases. (E) Single-cell RNA sequencing of IL2 receptor subunit expression on immune cells. Expression is localized to: IL2RΑ (Treg), IL2RB (CD8, NK cell), and IL2RG (all immune cells). (F) Expression of PD-1 by CD8 T cells of non-responders (NR) and responders (R) pre-treatment. (G and H) Enrichment curves for KEGG (G) CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION and (H) KEGG JAK_STAT_SIGNALING_PATHWAY from RNA sequencing data in responder vs. non-responder tumors treated with neoadjuvant SBRT and durvalumab. RNA sequencing on tumors was performed on tumors taken at baseline, pre-treatment time point. (I and J) Soluble IL-2 expression in pg/mL (I) from human plasma in responders and non-responders and (J) between pre- and post-neoadjuvant and surgery in responders and non-responders. (K) Normalized RNA sequencing expression of IL2RA and IL2RB in responders and non-responders. Human samples were obtained from 21 patients pre- and post-treatment. Data are presented as mean ± SEM. ∗p < 0.05, ∗∗p < 0.005, ∗∗∗p < 0.0005, ∗∗∗∗p < 0.0001.
Buv395 Pd 1 J43, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/primary+antibody+against+pdcd1/anti+cd4/pmc10439274-368-51-54
Average 90 stars, based on 1 article reviews
buv395-pd-1 j43 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier
cd90.2 53-2.1) buv396  (Becton Dickinson)
90
Becton Dickinson cd90.2 53-2.1) buv396
Clinical expression <t>of</t> <t>PD-1</t> and IL-2 receptors on lymphocytes in head and neck cancer (A and B) Cell mapping of HNSCC datasets from TISCH single-cell RNA sequencing database. (C) Single-cell RNA sequencing of TISCH HNSCC datasets showing PD-1 expression being localized primarily on T cells. (D) Heatmap showing differential expression of PD-1 across immune cell types gathered from TISCH single-cell RNA sequencing databases. (E) Single-cell RNA sequencing of IL2 receptor subunit expression on immune cells. Expression is localized to: IL2RΑ (Treg), IL2RB (CD8, NK cell), and IL2RG (all immune cells). (F) Expression of PD-1 by CD8 T cells of non-responders (NR) and responders (R) pre-treatment. (G and H) Enrichment curves for KEGG (G) CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION and (H) KEGG JAK_STAT_SIGNALING_PATHWAY from RNA sequencing data in responder vs. non-responder tumors treated with neoadjuvant SBRT and durvalumab. RNA sequencing on tumors was performed on tumors taken at baseline, pre-treatment time point. (I and J) Soluble IL-2 expression in pg/mL (I) from human plasma in responders and non-responders and (J) between pre- and post-neoadjuvant and surgery in responders and non-responders. (K) Normalized RNA sequencing expression of IL2RA and IL2RB in responders and non-responders. Human samples were obtained from 21 patients pre- and post-treatment. Data are presented as mean ± SEM. ∗p < 0.05, ∗∗p < 0.005, ∗∗∗p < 0.0005, ∗∗∗∗p < 0.0001.
Cd90.2 53 2.1) Buv396, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/primary+antibody+against+pdcd1/cd90+antibody/pmc08741417__mmc1-34-106-107
Average 90 stars, based on 1 article reviews
cd90.2 53-2.1) buv396 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier
pd-1(cd279)-bv421  (Becton Dickinson)
90
Becton Dickinson pd-1(cd279)-bv421
GCTfh cell, Pre-Tfh cell, and GC B cell gating strategy (A) Lymphocytes were identified using SSC versus FSC. The gated lymphocyte population was then plotted on CD20 versus CD3 to identify CD3+CD20- T cells. CD3+ T cells were then further plotted for CD4 expression to identify CD3+CD4+ T cells. CD45RA was then used to identify the CD3+CD4+CD45RA-memory T cells. Memory CD4+ T cells were plotted for CD25 and CD127 expression to exclude the CD25 high CD127- T regulatory cells from further analysis. Finally, CD25 low CD4+CD45RA- T cells were then plotted <t>for</t> <t>PD-1</t> versus CXCR5 to identify the PD-1 high CXCR5+ GC Tfh cells (red box). From this plot, precursor Tfh cells (Pre-Tfh) were also identified as PD-1 medium CXCR5 medium cells (purple box). (B) Lymphocytes were identified using SSC versus FSC. The gated lymphocyte population was then plotted on CD20 versus CD3 to identify CD20+ CD3- B cells. CD20 + B cells were then plotted on CD38 versus Bcl6 expression to identify the CD38 high Bcl6+CD20 + B cells (red box). See also and .
Pd 1(cd279) Bv421, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/primary+antibody+against+pdcd1/anti+cd3/pmc08741621-15-0-2
Average 90 stars, based on 1 article reviews
pd-1(cd279)-bv421 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier
cd279apc (pd-1  (Becton Dickinson)
90
Becton Dickinson cd279apc (pd-1
GCTfh cell, Pre-Tfh cell, and GC B cell gating strategy (A) Lymphocytes were identified using SSC versus FSC. The gated lymphocyte population was then plotted on CD20 versus CD3 to identify CD3+CD20- T cells. CD3+ T cells were then further plotted for CD4 expression to identify CD3+CD4+ T cells. CD45RA was then used to identify the CD3+CD4+CD45RA-memory T cells. Memory CD4+ T cells were plotted for CD25 and CD127 expression to exclude the CD25 high CD127- T regulatory cells from further analysis. Finally, CD25 low CD4+CD45RA- T cells were then plotted <t>for</t> <t>PD-1</t> versus CXCR5 to identify the PD-1 high CXCR5+ GC Tfh cells (red box). From this plot, precursor Tfh cells (Pre-Tfh) were also identified as PD-1 medium CXCR5 medium cells (purple box). (B) Lymphocytes were identified using SSC versus FSC. The gated lymphocyte population was then plotted on CD20 versus CD3 to identify CD20+ CD3- B cells. CD20 + B cells were then plotted on CD38 versus Bcl6 expression to identify the CD38 high Bcl6+CD20 + B cells (red box). See also and .
Cd279apc (Pd 1, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/primary+antibody+against+pdcd1/cd279apc++pd+1+antibody/pm37535195-40-33-37
Average 90 stars, based on 1 article reviews
cd279apc (pd-1 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

Image Search Results


Representative flow cytometry plots gated on CD8 + T-cells for a Chro individual showing A. Cellular proliferation (CFSElow), B. IFNγ production, and C . HLA-DR⁺CD38⁺ expression. Pair-wise comparison on the percentage of CFSE low , IFNγ and HLA-DR⁺CD38⁺ expression in response to the corresponding HIV peptides (HIV-1-Gag peptide pool for Et and Chro groups and HIVConsv peptide pool for Etvac) in the presence of αPD-1, αTIM-3, αPD-1+αTIM-3 (Combo) antibodies and isotype control antibodies in D. Etvac, E. Et and F. Chro study groups. The dots represent a sample tested. The Wilcoxon matched-pairs signed ranked test was used to calculate statistical differences. P-values: ns > 0.05, *<0.05, **<0.005 and ***<0.0005.

Journal: bioRxiv

Article Title: PD-1 blockade enhances HIV-1 vaccine-induced CD8⁺ T-cell responses in PWH early ART-treated

doi: 10.1101/2024.07.05.601669

Figure Lengend Snippet: Representative flow cytometry plots gated on CD8 + T-cells for a Chro individual showing A. Cellular proliferation (CFSElow), B. IFNγ production, and C . HLA-DR⁺CD38⁺ expression. Pair-wise comparison on the percentage of CFSE low , IFNγ and HLA-DR⁺CD38⁺ expression in response to the corresponding HIV peptides (HIV-1-Gag peptide pool for Et and Chro groups and HIVConsv peptide pool for Etvac) in the presence of αPD-1, αTIM-3, αPD-1+αTIM-3 (Combo) antibodies and isotype control antibodies in D. Etvac, E. Et and F. Chro study groups. The dots represent a sample tested. The Wilcoxon matched-pairs signed ranked test was used to calculate statistical differences. P-values: ns > 0.05, *<0.05, **<0.005 and ***<0.0005.

Article Snippet: Cells were washed with 1x PBS and surface stained with CD8 (AmCyan, clone RPA-T8, BD), HLA-DR (PerCP-Cy5.5, clone G46-6, BD), CD38 (APC, clone HB-7, Biolegend), PD-1 (BV421, clone EH12.1, BD) and TIM-3 (PE, clone F38-2E2, Biolegend) antibodies for 25 minutes.

Techniques: Flow Cytometry, Expressing, Comparison, Control

Waterfall plots represent the magnitude of proliferation (CFSE low ), IFNγ and HLA-DR⁺CD38⁺ as FCh of each condition from the Isotype control. A. All study groups combined (n=33), B. Etvac (n=11), C. Et (n=13) and D. Chro (n=9). The bars represent the FCh per sample tested. The statistical linear mixed-effects model calculates differences using αPD-1 as a reference group. P-values: ns>0.05, *<0.05, **<0.005 and ***<0.0005.

Journal: bioRxiv

Article Title: PD-1 blockade enhances HIV-1 vaccine-induced CD8⁺ T-cell responses in PWH early ART-treated

doi: 10.1101/2024.07.05.601669

Figure Lengend Snippet: Waterfall plots represent the magnitude of proliferation (CFSE low ), IFNγ and HLA-DR⁺CD38⁺ as FCh of each condition from the Isotype control. A. All study groups combined (n=33), B. Etvac (n=11), C. Et (n=13) and D. Chro (n=9). The bars represent the FCh per sample tested. The statistical linear mixed-effects model calculates differences using αPD-1 as a reference group. P-values: ns>0.05, *<0.05, **<0.005 and ***<0.0005.

Article Snippet: Cells were washed with 1x PBS and surface stained with CD8 (AmCyan, clone RPA-T8, BD), HLA-DR (PerCP-Cy5.5, clone G46-6, BD), CD38 (APC, clone HB-7, Biolegend), PD-1 (BV421, clone EH12.1, BD) and TIM-3 (PE, clone F38-2E2, Biolegend) antibodies for 25 minutes.

Techniques: Control

Correlograms indicate correlations between parameters across study groups: Etvac (n=11), Et (n=13) and Chro (n=9) for each experimental condition (HIV-1 for peptide stimulation, HIV+αTIM-3, HIV+αPD-1 and HIV+Combo). The top of the diagonal shows Spearman’s rank correlation coefficient with p-value<0.05. The colour and size of the circles indicate the strength and direction of the correlation. The bottom of the diagonal represents the linear regression. p-values: ns>0.05, *<0.05, **<0.005 and ***<0.0005.

Journal: bioRxiv

Article Title: PD-1 blockade enhances HIV-1 vaccine-induced CD8⁺ T-cell responses in PWH early ART-treated

doi: 10.1101/2024.07.05.601669

Figure Lengend Snippet: Correlograms indicate correlations between parameters across study groups: Etvac (n=11), Et (n=13) and Chro (n=9) for each experimental condition (HIV-1 for peptide stimulation, HIV+αTIM-3, HIV+αPD-1 and HIV+Combo). The top of the diagonal shows Spearman’s rank correlation coefficient with p-value<0.05. The colour and size of the circles indicate the strength and direction of the correlation. The bottom of the diagonal represents the linear regression. p-values: ns>0.05, *<0.05, **<0.005 and ***<0.0005.

Article Snippet: Cells were washed with 1x PBS and surface stained with CD8 (AmCyan, clone RPA-T8, BD), HLA-DR (PerCP-Cy5.5, clone G46-6, BD), CD38 (APC, clone HB-7, Biolegend), PD-1 (BV421, clone EH12.1, BD) and TIM-3 (PE, clone F38-2E2, Biolegend) antibodies for 25 minutes.

Techniques:

A. netSNE visualization of flow cytometry data for Isotype and PD-1 blockade condition in Etvac (127.142 events). Each panel represents the fluorochrome intensity of CFSE, IFNγ, HLA-DR and CD38 for each recorded event. B. Clustering analysis of cells in netSNE space by KNN algorithm. The percentage of the total cells comprised in each cluster is indicated. C. Heatmap of the median normalised biexponential-transformed intensity for each marker. The dendrogram shows the association between clusters based on the intensity of each fluorochrome. Two major nodes indicate proliferating (left node, #1, #6) and no proliferating (right nodes). D. Pairwise comparison of cluster #1 and #6 composition indicates the frequency of CD8⁺ T cells inside the cluster in isotype and αPD-1 conditions. E. Ultrasensitive p24 determination in the supernatant seven days after cell culture. The dotted line represents the limit of quantification (LOQ). P value<0.005(**). Unst (Unstimulated) SEB (Staphylococcal enterotoxin B). The Wilcoxon matched pairs signed ranked test was used to determine statistical significance. p-values: ns>0.05, *<0.05, **<0.005 and ***<0.0005.

Journal: bioRxiv

Article Title: PD-1 blockade enhances HIV-1 vaccine-induced CD8⁺ T-cell responses in PWH early ART-treated

doi: 10.1101/2024.07.05.601669

Figure Lengend Snippet: A. netSNE visualization of flow cytometry data for Isotype and PD-1 blockade condition in Etvac (127.142 events). Each panel represents the fluorochrome intensity of CFSE, IFNγ, HLA-DR and CD38 for each recorded event. B. Clustering analysis of cells in netSNE space by KNN algorithm. The percentage of the total cells comprised in each cluster is indicated. C. Heatmap of the median normalised biexponential-transformed intensity for each marker. The dendrogram shows the association between clusters based on the intensity of each fluorochrome. Two major nodes indicate proliferating (left node, #1, #6) and no proliferating (right nodes). D. Pairwise comparison of cluster #1 and #6 composition indicates the frequency of CD8⁺ T cells inside the cluster in isotype and αPD-1 conditions. E. Ultrasensitive p24 determination in the supernatant seven days after cell culture. The dotted line represents the limit of quantification (LOQ). P value<0.005(**). Unst (Unstimulated) SEB (Staphylococcal enterotoxin B). The Wilcoxon matched pairs signed ranked test was used to determine statistical significance. p-values: ns>0.05, *<0.05, **<0.005 and ***<0.0005.

Article Snippet: Cells were washed with 1x PBS and surface stained with CD8 (AmCyan, clone RPA-T8, BD), HLA-DR (PerCP-Cy5.5, clone G46-6, BD), CD38 (APC, clone HB-7, Biolegend), PD-1 (BV421, clone EH12.1, BD) and TIM-3 (PE, clone F38-2E2, Biolegend) antibodies for 25 minutes.

Techniques: Flow Cytometry, Transformation Assay, Marker, Comparison, Cell Culture

A. Heatmap of the Cytokine profiling across study groups (n=104 experimental conditions). B. Waterfall plots show secreted cytokines in Etvac (n=8) or Chro (n=7) in response to αPD-1 represented as the fold Change (FCh) from the isotype control condition. C . Waterfall plots of IL-5 and IL-13 production Etvac (yellow), Et (red) and Chro (green) groups upon αPD-1 treatment. The heatmap colour scale indicates the standardized FCh of each cytokine across all samples. The bars represent a sample FCh per individual tested. The linear mixed model was used to determine statistical significance using αPD-1 as a reference group. p-values: ns>0.05, *<0.05, **<0.005 and ***<0.0005.

Journal: bioRxiv

Article Title: PD-1 blockade enhances HIV-1 vaccine-induced CD8⁺ T-cell responses in PWH early ART-treated

doi: 10.1101/2024.07.05.601669

Figure Lengend Snippet: A. Heatmap of the Cytokine profiling across study groups (n=104 experimental conditions). B. Waterfall plots show secreted cytokines in Etvac (n=8) or Chro (n=7) in response to αPD-1 represented as the fold Change (FCh) from the isotype control condition. C . Waterfall plots of IL-5 and IL-13 production Etvac (yellow), Et (red) and Chro (green) groups upon αPD-1 treatment. The heatmap colour scale indicates the standardized FCh of each cytokine across all samples. The bars represent a sample FCh per individual tested. The linear mixed model was used to determine statistical significance using αPD-1 as a reference group. p-values: ns>0.05, *<0.05, **<0.005 and ***<0.0005.

Article Snippet: Cells were washed with 1x PBS and surface stained with CD8 (AmCyan, clone RPA-T8, BD), HLA-DR (PerCP-Cy5.5, clone G46-6, BD), CD38 (APC, clone HB-7, Biolegend), PD-1 (BV421, clone EH12.1, BD) and TIM-3 (PE, clone F38-2E2, Biolegend) antibodies for 25 minutes.

Techniques: Control

A Basal expression of inhibitory receptors and HLA-DR⁺CD38⁺ expression in PBMCs from Etvac (n=10), Et (n=13) and Chro (n=9) individuals before the immune checkpoint blockade assay. B Correlations between the percentage of CFSE-Low, IFNγ production and HLA-DR⁺CD38⁺ in anti-PD-1 blockade and PD-1 expression in CD8 + T cells. Mann–Whitney test was used to compare differences between groups. Spearman correlations between Basal PD-1 levels (frequency) and the functional parameters determined on day 7 upon PD-1 blockade, p-values: ns>0.05, *<0.05, **<0.005 and ***<0.0005.

Journal: bioRxiv

Article Title: PD-1 blockade enhances HIV-1 vaccine-induced CD8⁺ T-cell responses in PWH early ART-treated

doi: 10.1101/2024.07.05.601669

Figure Lengend Snippet: A Basal expression of inhibitory receptors and HLA-DR⁺CD38⁺ expression in PBMCs from Etvac (n=10), Et (n=13) and Chro (n=9) individuals before the immune checkpoint blockade assay. B Correlations between the percentage of CFSE-Low, IFNγ production and HLA-DR⁺CD38⁺ in anti-PD-1 blockade and PD-1 expression in CD8 + T cells. Mann–Whitney test was used to compare differences between groups. Spearman correlations between Basal PD-1 levels (frequency) and the functional parameters determined on day 7 upon PD-1 blockade, p-values: ns>0.05, *<0.05, **<0.005 and ***<0.0005.

Article Snippet: Cells were washed with 1x PBS and surface stained with CD8 (AmCyan, clone RPA-T8, BD), HLA-DR (PerCP-Cy5.5, clone G46-6, BD), CD38 (APC, clone HB-7, Biolegend), PD-1 (BV421, clone EH12.1, BD) and TIM-3 (PE, clone F38-2E2, Biolegend) antibodies for 25 minutes.

Techniques: Expressing, MANN-WHITNEY, Functional Assay

Clinical expression of PD-1 and IL-2 receptors on lymphocytes in head and neck cancer (A and B) Cell mapping of HNSCC datasets from TISCH single-cell RNA sequencing database. (C) Single-cell RNA sequencing of TISCH HNSCC datasets showing PD-1 expression being localized primarily on T cells. (D) Heatmap showing differential expression of PD-1 across immune cell types gathered from TISCH single-cell RNA sequencing databases. (E) Single-cell RNA sequencing of IL2 receptor subunit expression on immune cells. Expression is localized to: IL2RΑ (Treg), IL2RB (CD8, NK cell), and IL2RG (all immune cells). (F) Expression of PD-1 by CD8 T cells of non-responders (NR) and responders (R) pre-treatment. (G and H) Enrichment curves for KEGG (G) CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION and (H) KEGG JAK_STAT_SIGNALING_PATHWAY from RNA sequencing data in responder vs. non-responder tumors treated with neoadjuvant SBRT and durvalumab. RNA sequencing on tumors was performed on tumors taken at baseline, pre-treatment time point. (I and J) Soluble IL-2 expression in pg/mL (I) from human plasma in responders and non-responders and (J) between pre- and post-neoadjuvant and surgery in responders and non-responders. (K) Normalized RNA sequencing expression of IL2RA and IL2RB in responders and non-responders. Human samples were obtained from 21 patients pre- and post-treatment. Data are presented as mean ± SEM. ∗p < 0.05, ∗∗p < 0.005, ∗∗∗p < 0.0005, ∗∗∗∗p < 0.0001.

Journal: Cell Reports Medicine

Article Title: Selective targeting of IL2Rβγ combined with radiotherapy triggers CD8- and NK-mediated immunity, abrogating metastasis in HNSCC

doi: 10.1016/j.xcrm.2023.101150

Figure Lengend Snippet: Clinical expression of PD-1 and IL-2 receptors on lymphocytes in head and neck cancer (A and B) Cell mapping of HNSCC datasets from TISCH single-cell RNA sequencing database. (C) Single-cell RNA sequencing of TISCH HNSCC datasets showing PD-1 expression being localized primarily on T cells. (D) Heatmap showing differential expression of PD-1 across immune cell types gathered from TISCH single-cell RNA sequencing databases. (E) Single-cell RNA sequencing of IL2 receptor subunit expression on immune cells. Expression is localized to: IL2RΑ (Treg), IL2RB (CD8, NK cell), and IL2RG (all immune cells). (F) Expression of PD-1 by CD8 T cells of non-responders (NR) and responders (R) pre-treatment. (G and H) Enrichment curves for KEGG (G) CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION and (H) KEGG JAK_STAT_SIGNALING_PATHWAY from RNA sequencing data in responder vs. non-responder tumors treated with neoadjuvant SBRT and durvalumab. RNA sequencing on tumors was performed on tumors taken at baseline, pre-treatment time point. (I and J) Soluble IL-2 expression in pg/mL (I) from human plasma in responders and non-responders and (J) between pre- and post-neoadjuvant and surgery in responders and non-responders. (K) Normalized RNA sequencing expression of IL2RA and IL2RB in responders and non-responders. Human samples were obtained from 21 patients pre- and post-treatment. Data are presented as mean ± SEM. ∗p < 0.05, ∗∗p < 0.005, ∗∗∗p < 0.0005, ∗∗∗∗p < 0.0001.

Article Snippet: For analysis of immune cells, the following antibodies were: PerCP–CD45 (clone: 30-F11, Biolegend), BUV805–CD3 (clone: 17A2, BD Biosciences), BUV 496-CD4 (clone: GK1.5, BD Biosciences), BB515-CD8 (clone: 53–6.7, BD Biosciences), BV570-CD44 (clone: IM7, Biolegend), PE-Cy7-NKp46 (clone: 29A1.4, Biolegend), Superbright 436-CD69 (clone: H1.2F3, eBioscience), BV605-DNAM-1 (clone: TX42.1, Biolegend), BV786-CD25 (clone: 3C7, BD Biosciences), BUV395-PD-1 (clone: J43, BD Biosciences), BV650-PD-L1 (clone: MIH5, BD BioSciences), PE-Cy5-CD11c (clone: N418, Biolegend), PE/Dazzle 594-MHC II (clone M5/114.15.2, Biolegend), PerCP-Cy5.5-CD80 (clone: 16-10A1, Biolegend), BUV661-CD11b (clone: M1/70, BD Biosciences), Alexa Fluor 647-Ly6C (clone: HK1.4, Biolegend), BV421-Ly6G (clone: 1A8, Biolegend), Alexa Fluor 700-CD19 (clone: 6D5, Biolegend), BV480-F4/80 (clone: T45-2342), eFluor 450-iNOS (clone: CXNFT, eBioscience), PE-CD163 (clone: S15049F, Biolegend), APC-eFluor 780-Ki-67 (clone: SolA15, eBioscience), Alexa Fluor 532-Foxp3 (clone: FjK-16s, eBioscience), APC-IL-2 (clone: JES6-5H4, eBioscience), BUV737-IFNγ (clone: XMG1.2, BD Biosciences), FITC-Granzyme B (clone: QA16A02, Biolegend), BV750-TNFα (clone: MP6-XT22, Biolegend), BV711-IL-10 (clone: JES5-16E3, BD Bioscience), PE-pan-cytokeratin (clone: AE-1/AE-3, Novus Biologicals), BV650-EpCAM (clone: G8.8, Biolegend), Alexafluor 488-pan cytokeratin (clone: AE1/AE3, Invitrogen) Alexafluor 700-NK1.1 (clone: S17016D, Biolegend), eFluor450-CD122 (clone: TM-b1, eBioscience), PE/Dazzle594-CD25 (clone: C37, Biolegend), Alexafluor 647-CD11b (clone: M1/70, Biolegend), BV711-NKG2D (clone: CX5, BD Bioscience), PerCP-eFluor 710-NKG2A (clone: 20d5, eBioscience), BUV661-Ly49H (clone: 3D10, BD Bioscience), PerCP-Cy5.5-KLRG1 (clone: 2F1, BD Bioscience), PE-LFA-1 (clone: H155-78, Biolegend), Superbright 436-CXCR3 (clone: CXCR3-173, eBioscience), BV421-NKG2I (clone: 854929, BD Bioscience), FITC-Ly49G2 (clone: 4D11, eBioscience), BV786-Ly49A (clone: A1, BD Bioscience), AP/Fire 810 -CD25 (clone PC61, Biolegend), BV480-CD27 (clone LG.3A10, BD Bioscience), BV650-CD11b (clone M1/70, Biolegend), Superbright 436-NKG2D (clone CX5, eBioscience), BUV615-PD-1 (clone RMP1-30, BD Bioscience), PerCP-eFluor710-CD107a (clone 1D4B, eBioscience), PerCP-Cy5.5-LFA-1 (clone H155-78, Biolegend), Alexa Fluor 700-MHC II (clone M5/114.15.2, Biolegend), BUV395-CD103 (clone 2E7, BD Bioscience), eFluor 450-CXCR4 (clone 2B11, eBioscience), Alexa Fluor 647, pZAP70 (clone 17A/P-ZAP70, BD Bioscience), APC-pSTAT5 (clone SRBCZX, eBioscience), BV785-IL-2 (clone JES6-5H4, Biolegend), PE-TCF-7/TCF-1 (clone S33-966, BD Bioscience), PE/Dazzle 594-Granzyme B (clone QA16A02, Biolegend), BV421-Tbet (clone 4B10, Biolegend), Alexa Fluor 488-pCD3 zeta (clone 3ZBR4S, eBioscience).

Techniques: Expressing, RNA Sequencing Assay

Journal: Cell Reports Medicine

Article Title: Selective targeting of IL2Rβγ combined with radiotherapy triggers CD8- and NK-mediated immunity, abrogating metastasis in HNSCC

doi: 10.1016/j.xcrm.2023.101150

Figure Lengend Snippet:

Article Snippet: For analysis of immune cells, the following antibodies were: PerCP–CD45 (clone: 30-F11, Biolegend), BUV805–CD3 (clone: 17A2, BD Biosciences), BUV 496-CD4 (clone: GK1.5, BD Biosciences), BB515-CD8 (clone: 53–6.7, BD Biosciences), BV570-CD44 (clone: IM7, Biolegend), PE-Cy7-NKp46 (clone: 29A1.4, Biolegend), Superbright 436-CD69 (clone: H1.2F3, eBioscience), BV605-DNAM-1 (clone: TX42.1, Biolegend), BV786-CD25 (clone: 3C7, BD Biosciences), BUV395-PD-1 (clone: J43, BD Biosciences), BV650-PD-L1 (clone: MIH5, BD BioSciences), PE-Cy5-CD11c (clone: N418, Biolegend), PE/Dazzle 594-MHC II (clone M5/114.15.2, Biolegend), PerCP-Cy5.5-CD80 (clone: 16-10A1, Biolegend), BUV661-CD11b (clone: M1/70, BD Biosciences), Alexa Fluor 647-Ly6C (clone: HK1.4, Biolegend), BV421-Ly6G (clone: 1A8, Biolegend), Alexa Fluor 700-CD19 (clone: 6D5, Biolegend), BV480-F4/80 (clone: T45-2342), eFluor 450-iNOS (clone: CXNFT, eBioscience), PE-CD163 (clone: S15049F, Biolegend), APC-eFluor 780-Ki-67 (clone: SolA15, eBioscience), Alexa Fluor 532-Foxp3 (clone: FjK-16s, eBioscience), APC-IL-2 (clone: JES6-5H4, eBioscience), BUV737-IFNγ (clone: XMG1.2, BD Biosciences), FITC-Granzyme B (clone: QA16A02, Biolegend), BV750-TNFα (clone: MP6-XT22, Biolegend), BV711-IL-10 (clone: JES5-16E3, BD Bioscience), PE-pan-cytokeratin (clone: AE-1/AE-3, Novus Biologicals), BV650-EpCAM (clone: G8.8, Biolegend), Alexafluor 488-pan cytokeratin (clone: AE1/AE3, Invitrogen) Alexafluor 700-NK1.1 (clone: S17016D, Biolegend), eFluor450-CD122 (clone: TM-b1, eBioscience), PE/Dazzle594-CD25 (clone: C37, Biolegend), Alexafluor 647-CD11b (clone: M1/70, Biolegend), BV711-NKG2D (clone: CX5, BD Bioscience), PerCP-eFluor 710-NKG2A (clone: 20d5, eBioscience), BUV661-Ly49H (clone: 3D10, BD Bioscience), PerCP-Cy5.5-KLRG1 (clone: 2F1, BD Bioscience), PE-LFA-1 (clone: H155-78, Biolegend), Superbright 436-CXCR3 (clone: CXCR3-173, eBioscience), BV421-NKG2I (clone: 854929, BD Bioscience), FITC-Ly49G2 (clone: 4D11, eBioscience), BV786-Ly49A (clone: A1, BD Bioscience), AP/Fire 810 -CD25 (clone PC61, Biolegend), BV480-CD27 (clone LG.3A10, BD Bioscience), BV650-CD11b (clone M1/70, Biolegend), Superbright 436-NKG2D (clone CX5, eBioscience), BUV615-PD-1 (clone RMP1-30, BD Bioscience), PerCP-eFluor710-CD107a (clone 1D4B, eBioscience), PerCP-Cy5.5-LFA-1 (clone H155-78, Biolegend), Alexa Fluor 700-MHC II (clone M5/114.15.2, Biolegend), BUV395-CD103 (clone 2E7, BD Bioscience), eFluor 450-CXCR4 (clone 2B11, eBioscience), Alexa Fluor 647, pZAP70 (clone 17A/P-ZAP70, BD Bioscience), APC-pSTAT5 (clone SRBCZX, eBioscience), BV785-IL-2 (clone JES6-5H4, Biolegend), PE-TCF-7/TCF-1 (clone S33-966, BD Bioscience), PE/Dazzle 594-Granzyme B (clone QA16A02, Biolegend), BV421-Tbet (clone 4B10, Biolegend), Alexa Fluor 488-pCD3 zeta (clone 3ZBR4S, eBioscience).

Techniques: Purification, Recombinant, Staining, Lysis, Cell Isolation, Enzyme-linked Immunosorbent Assay, RNA Sequencing Assay, Software, Luminex

GCTfh cell, Pre-Tfh cell, and GC B cell gating strategy (A) Lymphocytes were identified using SSC versus FSC. The gated lymphocyte population was then plotted on CD20 versus CD3 to identify CD3+CD20- T cells. CD3+ T cells were then further plotted for CD4 expression to identify CD3+CD4+ T cells. CD45RA was then used to identify the CD3+CD4+CD45RA-memory T cells. Memory CD4+ T cells were plotted for CD25 and CD127 expression to exclude the CD25 high CD127- T regulatory cells from further analysis. Finally, CD25 low CD4+CD45RA- T cells were then plotted for PD-1 versus CXCR5 to identify the PD-1 high CXCR5+ GC Tfh cells (red box). From this plot, precursor Tfh cells (Pre-Tfh) were also identified as PD-1 medium CXCR5 medium cells (purple box). (B) Lymphocytes were identified using SSC versus FSC. The gated lymphocyte population was then plotted on CD20 versus CD3 to identify CD20+ CD3- B cells. CD20 + B cells were then plotted on CD38 versus Bcl6 expression to identify the CD38 high Bcl6+CD20 + B cells (red box). See also and .

Journal: iScience

Article Title: Early expansion of CD38+ICOS+ GC Tfh in draining lymph nodes during influenza vaccination immune response

doi: 10.1016/j.isci.2021.103656

Figure Lengend Snippet: GCTfh cell, Pre-Tfh cell, and GC B cell gating strategy (A) Lymphocytes were identified using SSC versus FSC. The gated lymphocyte population was then plotted on CD20 versus CD3 to identify CD3+CD20- T cells. CD3+ T cells were then further plotted for CD4 expression to identify CD3+CD4+ T cells. CD45RA was then used to identify the CD3+CD4+CD45RA-memory T cells. Memory CD4+ T cells were plotted for CD25 and CD127 expression to exclude the CD25 high CD127- T regulatory cells from further analysis. Finally, CD25 low CD4+CD45RA- T cells were then plotted for PD-1 versus CXCR5 to identify the PD-1 high CXCR5+ GC Tfh cells (red box). From this plot, precursor Tfh cells (Pre-Tfh) were also identified as PD-1 medium CXCR5 medium cells (purple box). (B) Lymphocytes were identified using SSC versus FSC. The gated lymphocyte population was then plotted on CD20 versus CD3 to identify CD20+ CD3- B cells. CD20 + B cells were then plotted on CD38 versus Bcl6 expression to identify the CD38 high Bcl6+CD20 + B cells (red box). See also and .

Article Snippet: PD-1(CD279)-BV421 , BD Biosciences , Cat# 562516; RRID: AB_11153482.

Techniques: Expressing

Functional T cell assay stimulants

Journal: iScience

Article Title: Early expansion of CD38+ICOS+ GC Tfh in draining lymph nodes during influenza vaccination immune response

doi: 10.1016/j.isci.2021.103656

Figure Lengend Snippet: Functional T cell assay stimulants

Article Snippet: PD-1(CD279)-BV421 , BD Biosciences , Cat# 562516; RRID: AB_11153482.

Techniques: Functional Assay, Concentration Assay

Journal: iScience

Article Title: Early expansion of CD38+ICOS+ GC Tfh in draining lymph nodes during influenza vaccination immune response

doi: 10.1016/j.isci.2021.103656

Figure Lengend Snippet:

Article Snippet: PD-1(CD279)-BV421 , BD Biosciences , Cat# 562516; RRID: AB_11153482.

Techniques: Recombinant, Software